Robert Thomas Freeman Sells 12,000 Shares of Alignment Healthcare, Inc. (NASDAQ:ALHC) Stock

Alignment Healthcare, Inc. (NASDAQ:ALHCGet Rating) CFO Robert Thomas Freeman sold 12,000 shares of the firm’s stock in a transaction dated Friday, June 17th. The stock was sold at an average price of $11.18, for a total transaction of $134,160.00. Following the completion of the transaction, the chief financial officer now directly owns 719,939 shares in the company, valued at $8,048,918.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Robert Thomas Freeman also recently made the following trade(s):

  • On Thursday, March 31st, Robert Thomas Freeman sold 4,944 shares of Alignment Healthcare stock. The stock was sold at an average price of $11.18, for a total transaction of $55,273.92.

Shares of ALHC traded up $0.41 during trading on Friday, reaching $11.37. 500,009 shares of the company traded hands, compared to its average volume of 625,808. Alignment Healthcare, Inc. has a twelve month low of $6.14 and a twelve month high of $27.74. The stock has a market cap of $2.13 billion, a PE ratio of -10.85 and a beta of 2.52. The stock has a 50-day simple moving average of $10.31 and a 200-day simple moving average of $10.37. The company has a quick ratio of 2.90, a current ratio of 2.90 and a debt-to-equity ratio of 0.52.

Alignment Healthcare (NASDAQ:ALHCGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. The firm had revenue of $345.53 million during the quarter, compared to analysts’ expectations of $332.93 million. Alignment Healthcare had a negative net margin of 14.38% and a negative return on equity of 56.68%. During the same quarter in the previous year, the business posted ($0.37) earnings per share. On average, equities research analysts predict that Alignment Healthcare, Inc. will post -0.97 EPS for the current year.

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC grew its holdings in shares of Alignment Healthcare by 1.4% in the third quarter. Geode Capital Management LLC now owns 592,579 shares of the company’s stock valued at $9,469,000 after purchasing an additional 8,060 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in Alignment Healthcare during the 3rd quarter worth approximately $400,000. Millennium Management LLC acquired a new position in Alignment Healthcare during the 3rd quarter worth approximately $2,382,000. Morgan Stanley grew its holdings in Alignment Healthcare by 41.5% during the 3rd quarter. Morgan Stanley now owns 973,869 shares of the company’s stock worth $15,563,000 after acquiring an additional 285,583 shares in the last quarter. Finally, NewEdge Wealth LLC acquired a new position in Alignment Healthcare during the 4th quarter worth approximately $141,000. Hedge funds and other institutional investors own 82.68% of the company’s stock.

ALHC has been the topic of several research reports. The Goldman Sachs Group decreased their price target on shares of Alignment Healthcare from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Tuesday, March 15th. William Blair reaffirmed an “outperform” rating on shares of Alignment Healthcare in a research note on Thursday, May 5th. Piper Sandler reduced their target price on shares of Alignment Healthcare from $25.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, February 24th. Bank of America raised shares of Alignment Healthcare from a “neutral” rating to a “buy” rating and reduced their target price for the stock from $18.00 to $14.00 in a research note on Thursday, May 26th. Finally, Morgan Stanley reduced their target price on shares of Alignment Healthcare from $21.00 to $18.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 7th. Ten analysts have rated the stock with a buy rating, According to MarketBeat, Alignment Healthcare presently has a consensus rating of “Buy” and a consensus target price of $17.89.

Alignment Healthcare Company Profile (Get Rating)

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform. It provides customized health care in the United States to seniors and those who need it through its Medicare advantage plans. The company owns Medicare advantage plans in the states of California, North Carolina, and Nevada.

See Also

Insider Buying and Selling by Quarter for Alignment Healthcare (NASDAQ:ALHC)

Receive News & Ratings for Alignment Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alignment Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.